Literature DB >> 3490450

Radiosensitization by cisplatin of RIF1 tumour cells in vitro.

A C Begg, P J van der Kolk, L Dewit, H Bartelink.   

Abstract

The ability of cis-diamminedichloroplatinum (II) (c-DDP) to enhance radiation-induced cell killing was tested on oxic RIF1 tumour cells in monolayer culture. Marked radiosensitization of the survivors of a 1 h drug treatment was found with all c-DDP doses tested, with enhancement ratios increasing from 1.2 to 2.2 with increasing drug dose. Isobologram analyses showed that the interactions of c-DDP with X-rays were supra-additive. To test whether part of the enhancement was due to a selection of subpopulations, the diploid and tetraploid RIF1 cells, which normally coexist in culture, were separated by unit gravity velocity sedimentation, and by developing diploid and tetraploid clones. Both methods showed that there was little difference in either drug sensitivity or radiation sensitivity between diploid and tetraploid cells. DNA histograms obtained by flow cytometry showed little or no cycle progression during the 1 h drug treatment. These data indicate that the radiosensitization was not the result of the drug exposure leaving cells in a radiosensitive phase. The observed radiosensitization, therefore, appears to have resulted from a true drug/X-ray interaction.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3490450     DOI: 10.1080/09553008614551291

Source DB:  PubMed          Journal:  Int J Radiat Biol Relat Stud Phys Chem Med        ISSN: 0020-7616


  9 in total

1.  Intratumoural administration of cisplatin in slow-release devices. I. Tumour response and toxicity.

Authors:  M J Deurloo; S Bohlken; W Kop; C F Lerk; W Hennink; H Bartelink; A C Begg
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

2.  A phase I trial of the oral platinum analogue JM216 with concomitant radiotherapy in advanced malignancies of the chest.

Authors:  C M George; D J Haraf; A M Mauer; S A Krauss; P C Hoffman; C M Rudin; L Szeto; E E Vokes
Journal:  Invest New Drugs       Date:  2001       Impact factor: 3.850

3.  Cyclopentenylcytosine does not enhance cisplatin-induced radiosensitization in human lung tumour cells.

Authors:  Hans M Rodermond; Rosemarie Ten Cate; Jaap Haveman; André VAN Kuilenburg; Jan Paul Medema; Chris VAN Bree; Nicolaas A P Franken
Journal:  Oncol Lett       Date:  2010-05-01       Impact factor: 2.967

4.  Preoperative radiation and chemotherapy in the treatment of adenocarcinoma of the rectum.

Authors:  R S Chari; D S Tyler; M S Anscher; L Russell; B M Clary; J Hathorn; H F Seigler
Journal:  Ann Surg       Date:  1995-06       Impact factor: 12.969

5.  Selective intra-arterial infusion of high-dose cisplatin in patients with advanced head and neck cancer results in high tumor platinum concentrations and cisplatin-DNA adduct formation.

Authors:  G Los; f A Blommaert; R Barton; D D Heath; L den Engelse; C Hanchett; D Vicario; R Weisman; K T Robbins; S B Howell
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

6.  Metformin enhances the radiosensitizing effect of cisplatin in non-small cell lung cancer cell lines with different cisplatin sensitivities.

Authors:  Muhammad Assad Riaz; Ali Sak; Yasin Bahadir Erol; Michael Groneberg; Jürgen Thomale; Martin Stuschke
Journal:  Sci Rep       Date:  2019-02-04       Impact factor: 4.379

7.  Cisplatin Reduces the Frequencies of Radiotherapy-Induced Micronuclei in Peripheral Blood Lymphocytes of Patients with Gynaecological Cancer: Possible Implications for the Risk of Second Malignant Neoplasms.

Authors:  Aneta Węgierek-Ciuk; Anna Lankoff; Halina Lisowska; Piotr Kędzierawski; Pamela Akuwudike; Lovisa Lundholm; Andrzej Wojcik
Journal:  Cells       Date:  2021-10-09       Impact factor: 6.600

8.  Survival benefit of adding chemotherapy to intensity modulated radiation in patients with locoregionally advanced nasopharyngeal carcinoma.

Authors:  Xuemei Ji; Conghua Xie; Desheng Hu; Xia Fan; Yajuan Zhou; Yingjie Zheng
Journal:  PLoS One       Date:  2013-02-18       Impact factor: 3.240

9.  Cisplatin-DNA adduct formation in patients treated with cisplatin-based chemoradiation: lack of correlation between normal tissues and primary tumor.

Authors:  F J P Hoebers; D Pluim; A A M Hart; M Verheij; A J M Balm; G Fons; C R N Rasch; J H M Schellens; L J A Stalpers; H Bartelink; A C Begg
Journal:  Cancer Chemother Pharmacol       Date:  2007-07-18       Impact factor: 3.333

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.